Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01534403
Recruitment Status : Completed
First Posted : February 16, 2012
Last Update Posted : May 6, 2016
Information provided by (Responsible Party):
UCB Pharma

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2015
  Actual Study Completion Date : February 2015
  Certification/Extension First Submitted : April 11, 2016